Title : Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.

Pub. Date : 1992 Feb 19

PMID : 1531148






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Fewer than 20% of patients with nonhematologic malignancies treated with chloroethylnitrosoureas (CENUs) respond, but streptozocin (STZ), which depletes O6-methylguanine-DNA-methyltransferase (MGMT), has been shown to reverse resistance to CENUs in vitro. 1-(2-chloroethyl)-1-nitrosourea O-6-methylguanine-DNA methyltransferase Homo sapiens
2 BACKGROUND: Fewer than 20% of patients with nonhematologic malignancies treated with chloroethylnitrosoureas (CENUs) respond, but streptozocin (STZ), which depletes O6-methylguanine-DNA-methyltransferase (MGMT), has been shown to reverse resistance to CENUs in vitro. 1-(2-chloroethyl)-1-nitrosourea O-6-methylguanine-DNA methyltransferase Homo sapiens
3 BACKGROUND: Fewer than 20% of patients with nonhematologic malignancies treated with chloroethylnitrosoureas (CENUs) respond, but streptozocin (STZ), which depletes O6-methylguanine-DNA-methyltransferase (MGMT), has been shown to reverse resistance to CENUs in vitro. 1-(2-chloroethyl)-1-nitrosourea O-6-methylguanine-DNA methyltransferase Homo sapiens